Status:
COMPLETED
Heritability of Polycystic Ovary Syndrome: Role of Antimullerian Hormone, Steroids and Leptin
Lead Sponsor:
University Hospital, Lille
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
18-43 years
Brief Summary
Polycystic ovary syndrome (PCOS) is the most common cause of ovulation disorders and affects 10 to 15% of women. Despite its frequency, its physiopathology remains unknown. In women, Anti-Müllerian h...
Eligibility Criteria
Inclusion
- Having a pre-conceptional infertility assessment in the gynecology-Endocrinology department of University Hospital of Lille
- in the first trimester of mono fetal pregnancy (between 5 and 10 weeks of gestation), obtained spontaneously, after induction of ovulation or Assisted Reproductive Techniques (ART)
- Pregnancy followed at University Hospital of Lille
- PCOS group: defined according to modified Rotterdam criteria (2003 and 2011)
- At least 2 of the following 3 criterion:
- Cycle disorder
- Clinical and / or biological hyperandrogenism
- Ovarian volume \> 10cm³ and/or more than 19 follicles from 2 to 9 mm per ovary
- After exclusion of other causes of cycle disorder or hyperandrogenism
- Control group: patient with severe male and / or tubal infertility, no cycling disorder, normal ovarian reserve (FSH\<10 IU / L, E2\<50 pg / ml, AMH\>7 and \<35 pmol / L and Follicles count between \>5 and \<20 per ovary at day 3 of the cycle).
- In the group of female controls, the fertility problem is not related to a female pathology of the hypothalamic-pituitary-ovarian axis (tubal or male infertility). They are women without ovarian personal pathology. The problem of fertility being of other origin.
Exclusion
- Multiple pregnancy
- Pregnancy after egg donation
- Long-term drug therapy (excluding routine pregnancy supplementation)
- Previous Diabetes
- Bariatric surgery
- Patients with ovulatory infertility of central or idiopathic origin
- Patients already included in another protocol
Key Trial Info
Start Date :
April 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 2 2022
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT03483792
Start Date
April 20 2018
End Date
June 2 2022
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Jeanne de Flandres, CHU
Lille, France